There may be a reason Pfizer chose that curious tagline in the drugmaker’s once-inescapable commercials for its COVID-19 oral antiviral – the subject of a “Saturday Night Live” parody – which cost U.S. taxpayers at least $12 billion before the feds tightened the spigot last fall and Pfizer jacked the price to $1,390 for a five-day course.
The nirmatrelvir-ritonavir combination marketed as Paxlovid does no better against so-called long COVID than a placebo taken with ritonavir, according to a new “original investigation” quietly released Friday in JAMA Internal Medicine, published by the Journal of the American Medical Association.
Read More